ArticleBMC cancer2018
Serum leucine-rich alpha-2-glycoprotein-1 with fucosylated triantennary N-glycan: a novel colorectal cancer marker.
Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 41 citations in OpenAlex.
- Novel Therapeutic Strategies and Biomarkers in the Management of Inflammatory Bowel Disease: A Narrative Review.Cureus · 2026Review
- Hepatocyte-derived LRG1 primes the liver for metastasis and impairs immunotherapy.Cellular & molecular immunology · 2026Article
- Fucose metabolism as a central axis linking inflammation, immunity, and cancer in the gut.Frontiers in immunology · 2026Review
- Machine learning for identifying liver and pancreas cancers through comprehensive serum glycopeptide spectra analysis: a case-control study.Molecular oncology · 2025Article
- The critical role of LRG1 in pathological fibrosis.Journal of molecular medicine (Berlin, Germany) · 2025Review
- Comprehensive serum glycopeptide spectra analysis to identify early-stage epithelial ovarian cancer.Scientific reports · 2024Article
- Crystal structure of LRG1 and the functional significance of LRG1 glycan for LPHN2 activation.Experimental & molecular medicine · 2023Article
- Review
- A new method for screening acute/chronic lymphocytic leukemia: dual-label time-resolved fluorescence immunoassay.BMC biotechnology · 2022Article
- Angiopathic activity of LRG1 is induced by the IL-6/STAT3 pathway.Scientific reports · 2022Article
- The role of leucine-rich alpha-2-glycoprotein-1 in proliferation, migration, and invasion of tumors.Journal of cancer research and clinical oncology · 2022Review
- LRG1: an emerging player in disease pathogenesis.Journal of biomedical science · 2022Review
- Role of Biomarkers in the Diagnosis and Treatment of Inflammatory Bowel Disease.Life (Basel, Switzerland) · 2021Review
- Serum exosome-derived biomarkers for the early detection of oral squamous cell carcinoma.Molecular and cellular biochemistry · 2021Article
- Temporal multi-omics identifies LRG1 as a vascular niche instructor of metastasis.Science translational medicine · 2021Article
- Identification of Fucosylated SERPINA1 as a Novel Plasma Marker for Pancreatic Cancer Using Lectin Affinity Capture Coupled with iTRAQ-Based Quantitative Glycoproteomics.International journal of molecular sciences · 2021Article
- Diagnostic performances of leucine-rich α-2-glycoprotein 1 and stem cell factor for diagnosis and follow-up of colorectal cancer.Journal, genetic engineering & biotechnology · 2021Article
- Research Progress on Leucine-Rich Alpha-2 Glycoprotein 1: A Review.Frontiers in pharmacology · 2021Review
- Evaluation of Serum Leucine-Rich Alpha-2 Glycoprotein as a New Inflammatory Biomarker of Inflammatory Bowel Disease.Mediators of inflammation · 2021Article
- The Prognostic Value of Leucine-RichBioMed research international · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCarcinoembryonic antigen (CEA) and carbohydrate antigen (CA)19-9 are used in clinical practice as tumor markers to diagnose or monitor colorectal cancer (CRC) patients, However, their specificities and sensitivities are not ideal, and novel alternatives are needed. In this study, mass spectrometry was used to search for screening markers, focusing on glycan alterations of glycoproteins in the sera of CRC patients.
methodsGlycopeptides were prepared from serum glycoproteins separated from blood samples of 80 CRC patients and 50 healthy volunteers, and their levels were measured by liquid chromatography time-of flight mass spectrometry (LC-TOF-MS).
resultsLeucine-rich alpha-2-glycoprotein-1 with fucosylated triantennary N-glycan (LRG-FTG) was identified as CRC marker after evaluating 30,000 candidate glycopeptide peaks. The average LRG-FTG level in CRC patients (1.25 ± 0.973 U/mL) was much higher than that in healthy volunteers (0.496 ± 0.433 U/mL, P < 10
conclusionsWe identified LRG-FTG as a new CRC marker, with a sensitivity and specificity exceeding CA19-9. The combination of LRG-FTG and CEA showed much higher sensitivity and specificity than each marker alone. Further validation beyond this initial exploratory cohort is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.